- /
- Supported exchanges
- / US
- / BBNX.NASDAQ
Beta Bionics, Inc. Common Stock (BBNX NASDAQ) stock market data APIs
Beta Bionics, Inc. Common Stock Financial Data Overview
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Beta Bionics, Inc. Common Stock (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Beta Bionics, Inc. Common Stock data using free add-ons & libraries
Get Beta Bionics, Inc. Common Stock Fundamental Data
Beta Bionics, Inc. Common Stock Fundamental data includes:
- Net Revenue: 88 570 K
- EBITDA: -67 327 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-29
- EPS/Forecast: -0.4117
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Beta Bionics, Inc. Common Stock News
New
Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026
IRVINE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today annou...
BBNX Crosses Above Average Analyst Target
In recent trading, shares of Beta Bionics Inc (Symbol: BBNX) have crossed above the average analyst 12-month target price of $31.30, changing hands for $31.34/share. When a stock reaches the target a...
Beta Bionics raises 2025 revenue guidance to $96.5M and projects Q4 gross margin improvement amid pharmacy channel expansion
Earnings Call Insights: Beta Bionics, Inc. (BBNX) Q3 2025 MANAGEMENT VIEW * CEO Sean Saint opened the call by highlighting "strong performance in the third quarter" and updated annual projections ...
Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance
IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial re...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.